Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26

DReAMzz is intended to refine dose selection before Phase 3, while substantial additional funding will be required beyond the current runway.

Rhea-AI Summary

Incannex Healthcare (IXHL) has begun first-patient dosing in its DReAMzz study of IHL-42X, as Stonegate Capital Partners updated coverage.

The study is enrolling approximately 120 patients across nine dose combinations and 14 U.S. sites, with completion expected in mid-2027. It aims to refine the dose ratio ahead of a planned Phase 3 program. Incannex had $68.4M of unrestricted cash as of September 24; management says this supports at least 12 months of planned spending. Substantial additional funding will be required beyond that period.

PSX-001 remains the principal secondary clinical asset. The Australian Phase 2 rheumatoid arthritis study of IHL-675A was terminated due to recruitment challenges and produced insufficient data to assess efficacy or safety.

4 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointFirst-patient dosing is underway in the DReAMzz study of IHL-42X.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Planned Phase 3 program will follow DReAMzz's intended refinement of the dose ratio.
• Moderate point. Forward-looking: it has not happened yet and may not happen.$68.4M unrestricted cash as of September 24 supports at least 12 months of planned spending, management says.
• Minor point. Forward-looking: it has not happened yet and may not happen.DReAMzz is enrolling approximately 120 patients across nine dose combinations and 14 U.S. sites; completion is expected mid-2027.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Substantial additional funding will be required beyond the period covered by the current cash runway.
• Moderate pointIHL-675A Australian Phase 2 study was terminated due to recruitment challenges, with insufficient data to assess efficacy or safety.

Key Figures

Study enrollment: Approximately 120 patients Dose combinations: 9 U.S. study sites: 14 +3 more

Study enrollment

Approximately 120 patients

DReAMzz study

Dose combinations

9

DReAMzz study

U.S. study sites

14

DReAMzz study

Expected study completion

Mid-2027

DReAMzz study

Unrestricted cash

$68.4M

As of September 24

Planned operations runway

At least 12 months

Management's stated support from the balance sheet

Historical Context

1 past event · Latest: Sep 09

1 event

1. Sep 09

   DReAMzz dosing update

   24h Move

   -4.5%

   DReAMzz dosing had begun at 13 U.S. sites, establishing the earlier execution status.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, phase 2, 10-k

3 terms

phase 3 medical

"ahead of the planned Phase 3 program"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2 medical

"Australian Phase 2 RA study was terminated"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

10-k regulatory

"the 10-K also explicitly says substantial additional funding"

A 10-K is a comprehensive annual report a public company files with the U.S. Securities and Exchange Commission that summarizes its business, financial results, risks, legal issues, and management discussion. Investors use it like a company’s detailed yearly report card and instruction manual — it helps reveal how the company makes money, where it might face trouble, and the underlying numbers that support valuation and investment decisions.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story from DReAMzz preparation into active clinical execution, with first-patient dosing underway and the balance sheet providing runway for at least 12 months of planned operations. The study is evaluating approximately 120 patients across nine dose combinations and 14 U.S. sites, with completion expected in mid-2027. In our view, the next several quarters should be measured primarily by enrollment cadence, dose optimization, and whether DReAMzz supports a more clearly defined Phase 3 design rather than near-term P&L trends. This sequencing should improve confidence in dose selection and Phase 3 trial design before IXHL commits to the higher development spending associated with late-stage studies.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• IHL-42X has moved from regulatory preparation into active clinical execution. DReAMzz is enrolling approximately 120 patients across nine dose combinations and 14 U.S. sites, with completion expected in mid-2027. The study is specifically intended to refine the dose ratio ahead of the planned Phase 3 program rather than replicate RePOSA's efficacy work.
• The balance sheet meaningfully reduces near-term financing pressure, but it does not eliminate longer-term capital requirements. IXHL had $68.4M of unrestricted cash as of September 24 and management says this supports at least 12 months of planned spending; the 10-K also explicitly says substantial additional funding will be required beyond that period.
• Pipeline prioritization has become clearer. PSX-001 remains the principal secondary clinical asset, while IHL-675A's Australian Phase 2 RA study was terminated due to recruitment challenges and produced insufficient data to assess efficacy or safety. The equity story is therefore increasingly concentrated around IHL-42X and the eventual DReAMzz-to-Phase 3 transition.

Click image above to view full announcement.

---

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/316910

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Incannex's DReAMzz study testing, and when is completion expected?

DReAMzz is evaluating approximately 120 patients across nine dose combinations and 14 U.S. sites, with completion expected in mid-2027. The study is intended to refine the IHL-42X dose ratio ahead of the planned Phase 3 program rather than replicate RePOSA's efficacy work.

How much cash does Incannex have, and how long is its funding runway?

Incannex had $68.4M of unrestricted cash as of September 24, which management says supports at least 12 months of planned spending. Substantial additional funding will be required beyond that period.